Skip to content

Craving Network Neurofeedback

Connectome-based Neurofeedback of the Craving Network to Reduce Food Cue Reactivity

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06426693
Enrollment
50
Registered
2024-05-23
Start date
2024-11-27
Completion date
2027-03-31
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or Obesity

Brief summary

This project tests whether individuals with overweight or obesity and high craving can learn to change their brain response to food cues using neurofeedback, to impact their craving and eating behavior.

Detailed description

Aim 1 of this study is to test whether neurofeedback from the craving network is associated with reduced craving network strength. Aim 2 of this study is to test whether neurofeedback from the craving network is associated with reduced food craving and changes in eating behavior. Aim 3 of this study is to test whether neurofeedback from the craving network is associated with changes in resting state functional connectivity.

Interventions

Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).

Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Ages 18 to 60 years * Body mass index \>25 kg/m2 * \>2.37 Food Craving Inventory score

Exclusion criteria

* Current or past 6 months use of anti-obesity medications * Weight-reduced state defined as \>10% weight reduction in the past 6 months. * Nicotine use * Current diagnosis of neurological or psychiatric disorder * Obesity-related diseases such as type-2 diabetes * Contraindications to MRI * Baseline scanning with motion \>0.15mm frame to frame displacement.

Design outcomes

Primary

MeasureTime frameDescription
Change in craving network strength during transfer runsWeek 1 and 3Craving network strength will be measured during transfer (i.e., no feedback) runs and compared across scan sessions.
Change in Food Craving Inventory Mean ScoreWeek 1, Week 7Food Craving Inventory has 28 items rated 1-5 and overall mean is calculated, range 1-5 with higher score indicating higher craving. FCI will be compared between baseline and 1 month follow-up.
Change in Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool Healthy Eating Index (HEI).Week 1, Week 7ASA-24 HEI is scored 0-100 with 100 indicating healthier diet and composite scores examined to interpret the overall score. HEI will be compared between baseline and 1 month follow-up.
Change in craving network strength during resting state runsWeek 1 and 3Craving network strength will be measured during resting state runs and compared across scan sessions.
Change in Food Rating Task healthiness, tastiness, and choice scoresWeek 1, Week 7Food Rating Task outcomes include healthiness, tastiness, and choice. Healthiness and tastiness mean score is taken, range 1-5, with 5 indicating higher healthiness or tastiness. Choice is counted from 0-48 items choosing the food item over the neutral reference food item, with higher values indicating more frequent choice. Food Ratings will be compared between baseline and 1 month follow-up.
Change in Food Snack Task caloric intakeWeek 1 and 3Food Snack Task will be used to measure caloric intake (out of a maximum value to calories offered) and compared across scan sessions.

Countries

United States

Contacts

Primary ContactKathleen A Garrison, PhD
kathleen.garrison@yale.edu2037376232

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026